[{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human iPSC-derived cardiac tissues","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"NanoSurface Biomedical \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ NIH"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The collaboration is designed to test ABC294640 (opaganib), a first-in-class, orally administered SPHK2 selective inhibitor, as a potential medical countermeasure to treat phosgene inhalation injury.

                          Brand Name : Yeliva

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Opaganib

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : Duke University School

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 03, 2020

                          Lead Product(s) : Human iPSC-derived cardiac tissues

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : NIH

                          Deal Size : $4.6 million

                          Deal Type : Funding

                          blank